Tyrosine Hydroxylase Deficiency: From Clinical and Therapeutic Features to Pathogenetic Considerations
Yoshiaki Furukawa · 2026
Read Tyrosine Hydroxylase Deficiency: From Clinical and Therapeutic Features to Pathogenetic Considerations by Yoshiaki Furukawa (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/openalex-w7220696744.txt.
Description
Yoshiaki Furukawa reviewed tyrosine hydroxylase deficiency in a 2026 article for a Japanese medical journal. The rare inherited disorder comes from bad variants in both copies of a gene whose enzyme performs the rate-limiting step in making dopamine and related messengers. With that step broken, patients lack dopamine first and the adrenaline family second, and most respond well to levodopa, the standard replacement therapy.
Its spectrum is very broad, and recent evidence shows why. There is no degeneration of dopamine neurons. Mildly affected patients may develop dopa-responsive dystonia through faulty receptor signaling after congenital dopamine shortage. Severely affected infants show major motor delay and react too strongly to levodopa. Because this brain system matures after birth, he argues, treatment should start as early as possible, starting such babies on very low levodopa doses to avoid intolerable side effects.
Catalog record
| CREATOR | Yoshiaki Furukawa |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 56 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | OpenAlex / Juntendō Igaku/Juntendo igaku |